The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Sodium-Glucose Cotransporter-2 Inhibitors May Decrease Gout Risk in Some Patients

Sodium-Glucose Cotransporter-2 Inhibitors May Decrease Gout Risk in Some Patients

February 19, 2020 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Although physicians prescribe sodium-glucose cotransporter-2 (SGLT2) inhibitors to treat type 2 diabetes, research suggests SGLT2 inhibitors may also reduce uric acid levels caused by glycosuria. This and other biologically plausible pathways have led researchers in several clinical trials to investigate whether SGLT2 inhibitors benefit adults without diabetes. Absent the results of clinical trials, some researchers have sought out real-world data to determine additional clinical applications of these drugs. Such data may be particularly useful. Since 2016, the 21st Century Cures Act directed the U.S. Food and Drug Administration (FDA) to consider the potential use of just such real-world data to help support the approval of new indications for approved drugs.

You Might Also Like
  • TNF Inhibitors May Not Be Linked to Cancer Risk in Kids
  • Older Gout Patients More Likely to Develop Hearing Impairment
  • New FDA Warnings: Patients on SGLT2 Inhibitors at Risk of Acute Kidney Injury & Loperamide Abuse on the Rise
Also By This Author
  • New Methodology to Improve Cartilage Repair

A recent study reports that adults with type 2 diabetes who are treated with an SGLT2 inhibitor have a lower rate of gout than adults treated with a glucagon-like peptide-1 (GLP-1) agonist. These findings withstood sensitivity analyses and, thus, are unlikely to be explained by unmeasured confounding factors. The research by Michael Fralick, MD, PhD, SM, a research fellow at Brigham and Women’s Hospital, Boston, and colleagues suggests SGLT2 inhibitors may reduce the risk for gout for adults with type 2 diabetes mellitus. The researchers published their findings online, Jan. 14 in the Annals of Internal Medicine.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The longitudinal study included approximately 300,000 adults with type 2 diabetes mellitus and no history of gout. However, the investigators note that, although they excluded patients with a history of gout, the team did not have access to important gout risk factors, such as alcohol use, a purine rich diet or body mass index. Despite this limitation, the researchers used their cohort to perform a one to one propensity score matching. They were able to match patients newly prescribed an SGLT2 inhibitor to patients newly prescribed a GLP1 agonist.

Of the patients newly prescribed an SGLT2 inhibitor, 636 were subsequently diagnosed with gout (4.9 events per 1,000 person-years). Comparatively, 836 individuals who were newly prescribed a GLP agonist were subsequently diagnosed with gout (8.2 events per 1,000 person-years). Thus, the researchers found the gout incidence rate was lower among patients prescribed an SGLT2 inhibitor than among those prescribed a GLP1 agonist. They calculated a hazard ratio of 0.64 and a rate difference of -2.9 per 1,000 person-years. When the investigators performed a sensitivity analysis with as much as one year of index medication exposure, they calculated an adjusted hazard ratio of 0.73.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The authors concluded their research by calculating an E-value for effects estimate of 2.50 for the primary outcome of gout rates in adults newly prescribed an SGLT2 inhibitor and those newly prescribed a GLP1 agonist. They balanced this calculation against an analysis of the incidence of hospitalization for heart failure, for which they calculated an adjusted hazard ratio of 0.63 for hospitalization for heart failure among patients prescribed SGLT2 inhibitors vs. those prescribed GLP1 agonists.

Pages: 1 2 | Single Page

Filed Under: Conditions, Crystal Arthritis Tagged With: Gout, Gout Resource Center, SGLT2 inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, type II diabetes

You Might Also Like:
  • TNF Inhibitors May Not Be Linked to Cancer Risk in Kids
  • Older Gout Patients More Likely to Develop Hearing Impairment
  • New FDA Warnings: Patients on SGLT2 Inhibitors at Risk of Acute Kidney Injury & Loperamide Abuse on the Rise
  • Gout, Glucose Metabolism and Obesity: A Case Review

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.